by Portfolio Grader | May 1, 2013 12:00 pm
This week, the overall grades of seven Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Genomic Health’s (NASDAQ:GHDX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In Portfolio Grader’s specific subcategory of Earnings Revisions, GHDX also gets an F. The stock currently has a trailing PE Ratio of 121.10. For a full analysis of GHDX stock, visit Portfolio Grader.
The rating of Acorda Therapeutics (NASDAQ:ACOR) declines this week from a C to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock.
The rating of Amarin (NASDAQ:AMRN) slips from a C to a D. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock gets F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. The stock price has dropped 8.2% over the past month, worse than the 2.3% increase the Nasdaq has seen over the same period of time. As of May 1, 2013, 18% of outstanding Amarin shares were held short. For more information, get Portfolio Grader’s complete analysis of AMRN stock.
Exelixis (NASDAQ:EXEL) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of May 1, 2013, 20.4% of outstanding Exelixis shares were held short. To get an in-depth look at EXEL, get Portfolio Grader’s complete analysis of EXEL stock.
Trius Therapeutics (NASDAQ:TSRX) gets weaker ratings this week as last week’s C drops to a D. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.
This week, Discovery Laboratories (NASDAQ:DSCO) drops from a C to a D rating. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. For a full analysis of DSCO stock, visit Portfolio Grader.
Slipping from a C to a D rating, Achillion (NASDAQ:ACHN) takes a hit this week. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also rates an F in Equity. As of May 1, 2013, 12.8% of outstanding Achillion shares were held short. For more information, get Portfolio Grader’s complete analysis of ACHN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/05/7-biotechnology-stocks-to-sell-now-ghdx-acor-amrn-4/
Short URL: http://invstplc.com/1nx0WYq
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.